KEYconversations in early-stage TNBC: Neo-Adjuvant therapy in early-stage triple-negative breast cancer. Beyond surgical downstaging

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

PDF,  1.78 MB

MSD’s sponsored symposium ‘KEYconversations in early-stage TNBC: Neo-Adjuvant therapy in early-stage triple-negative breast cancer. Beyond surgical downstaging’ took place at the annual Association of Breast Surgery Conference on the 16th May 2023 at the ICC Belfast. MSD supported logistics for ABS but had no influence over the scientific programme, this was a promotional symposium organised and fully funded by MSD.

The session consisted of speaker panel of two surgeons, Stuart McIntosh (Belfast) and Henry Cain (Newcastle), and one oncologist, Dr Melissa Phillips (Barts), to discuss the evolving surgical landscape and the unmet need for neo-adjuvant therapy, the KEYNOTE-522 trial, as well as some patient cases.

Download the resource to read a summary of the symposium.

Click on the resource to download.

KEYTRUDA, in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early-stage triple-negative breast cancer, at high-risk of recurrence.¹

Please refer to Summary of Product Characteristics for full list of AEs and management.

More information about KEYTRUDA® (pembrolizumab) in triple-negative breast cancer (TNBC)

Reference

1. KEYTRUDA Summary of Product Characteristics.

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website